Diligence memo · auto-generated · as of July 3, 2026

NEUROONE MEDICAL TECHNOLOGIES Corp

NEUROONE MEDICAL TECHNOLOGIES Corp looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

NEUROONE MEDICAL TECHNOLOGIES Corp operates in Biotechnology, based in EDEN PRAIRIE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

NEUROONE MEDICAL TECHNOLOGIES Corp has raised $21M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $13M on 2021-01-14.

Most recent recorded round closed around 2024-08-02.

Valuation (modeled)modeled

Provath models NEUROONE MEDICAL TECHNOLOGIES Corp at approximately $1.4M (range $301K–$2.9M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.03× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 23 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round was 45.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 68% of Biotechnology peers (4293 compared).

Modeled value ranks above 4% of those peers.

Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..

Peoplefiled

14 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.